Cargando…

Therapeutic targets in alcohol-associated liver disease: progress and challenges

Alcohol-associated liver disease (ALD) is a complex disease with rapidly increasing prevalence. Although there are promising therapeutic targets on the horizon, none of the newer targets is currently close to an Food and Drug Administration approval. Strategies are needed to overcome challenges in s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adekunle, Ayooluwatomiwa Deborah, Adejumo, Adeyinka, Singal, Ashwani K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176580/ https://www.ncbi.nlm.nih.gov/pubmed/37187673 http://dx.doi.org/10.1177/17562848231170946

Ejemplares similares

Mitochondrial dysfunction and alcohol-associated liver disease: a novel pathway and therapeutic target
por: Abdallah, Mohamed A., et al.
Publicado: (2020)

Covid-19 and alcohol associated liver disease
por: Deutsch-Link, Sasha, et al.
Publicado: (2022)

Integrated Multidisciplinary Management of Alcohol-associated Liver Disease
por: Holbeck, Malia, et al.
Publicado: (2023)

Editorial: Alcohol-associated liver disease—From pathogenesis to treatment
por: Kharbanda, Kusum K., et al.
Publicado: (2022)

3427 Racial and Gender Differences in Trends, Prevalence, and Outcomes for Non-alcoholic Fatty Liver Disease Hospitalizations in the US
por: Adejumo, Adeyinka Charles, et al.
Publicado: (2019)

Global burden of cirrhosis and liver cancer due to alcohol: the past, present, and the future
por: Xie, Chencheng, et al.
Publicado: (2023)

Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases
por: Raff, Evan J., et al.
Publicado: (2015)

3429 Inpatient Palliative Care Consultation Improves Readmissions in End-Stage Liver Disease
por: Adejumo, Adeyinka Charles
Publicado: (2019)

Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study
por: Adejumo, Adeyinka Charles, et al.
Publicado: (2017)

784: THE IMPACT OF THE CORONAVIRUS PANDEMIC AND GOVERNMENT LOCKDOWNS ON LIVER DISEASE HOSPITALIZATIONS, INPATIENT MORTALITY, AND LIVER TRANSPLANT SURGERY IN CALIFORNIA: A POPULATION-LEVEL ANALYSIS
por: Adekunle, Ayooluwatomiwa D., et al.
Publicado: (2022)

Alcohol‐Associated Liver Disease Before and After COVID‐19—An Overview and Call for Ongoing Investigation
por: Moon, Andrew M., et al.
Publicado: (2021)

Trends in gastrointestinal disease hospitalizations and outcomes during the first year of the coronavirus pandemic
por: Adekunle, Ayooluwatomiwa Deborah, et al.
Publicado: (2023)

Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer
por: Ravi, Sujan, et al.
Publicado: (2014)

Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis
por: Adejumo, Adeyinka Charles, et al.
Publicado: (2018)

PNPLA3 as a Genetic Determinant of Risk for and Severity of Non-alcoholic Fatty Liver Disease Spectrum
por: Salameh, Habeeb, et al.
Publicado: (2016)

Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
por: Seif El Dahan, Karim, et al.
Publicado: (2023)

Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges
por: Teng, Yu-Xian, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease-related hepatocellular carcinoma
por: Daher, Darine, et al.
Publicado: (2023)

Prevalence and Factors Affecting Occurrence of Type 2 Diabetes Mellitus in Saudi Patients with Chronic Liver Disease
por: Singal, Ashwani K., et al.
Publicado: (2008)

Severe Alcoholic Hepatitis: Atypical Presentation with Markedly Elevated Alkaline Phosphatase
por: Axley, Page, et al.
Publicado: (2017)

Alarming rate of 30-day hospital readmissions in patients with liver cirrhosis
por: Ebhohon, Ebehiwele, et al.
Publicado: (2021)

Problems and Challenges Associated with Renaming Non-alcoholic Fatty Liver Disease to Metabolic Associated Fatty Liver Disease
por: Zeng, Minghui, et al.
Publicado: (2023)

Esophago-Pleural Fistula Complicating a Laparoscopic Adjustable Gastric Band
por: Adekunle, Ayooluwatomiwa D., et al.
Publicado: (2022)

Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Ramai, Daryl, et al.
Publicado: (2021)

Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut–Liver Axis
por: Chen, Xiang, et al.
Publicado: (2022)

877: THE IMPACT OF THE CORONAVIRUS PANDEMIC AND GOVERNMENT LOCKDOWNS ON GASTROINTESTINAL DISEASE HOSPITALIZATIONS, INPATIENT MORTALITY, AND ENDOSCOPY UTILIZATION IN CALIFORNIA: A STATE-WIDE POPULATION-LEVEL ANALYSIS
por: Adekunle, Ayooluwatomiwa D., et al.
Publicado: (2022)

Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States
por: Adejumo, Adeyinka Charles, et al.
Publicado: (2019)

Ammonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis
por: Ravi, Sujan, et al.
Publicado: (2017)

Progress and challenges towards targeted delivery of cancer therapeutics
por: Rosenblum, Daniel, et al.
Publicado: (2018)

Experimental model and novel therapeutic targets for non-alcoholic fatty liver disease development
por: Jin, Yujin, et al.
Publicado: (2023)

Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets
por: Ding, Ya-Hui, et al.
Publicado: (2017)

The STING in Non-Alcoholic Fatty Liver Diseases: Potential Therapeutic Targets in Inflammation-Carcinogenesis Pathway
por: Lv, Juan, et al.
Publicado: (2022)

Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment
por: Oh, Hyunwoo, et al.
Publicado: (2016)

Sending an SOS: Healing the Liver with the Bone Marrow
por: Ayares, Gustavo, et al.
Publicado: (2022)

Challenges and Solutions in the Management of Hepatocellular Carcinoma Associated with Non-Alcoholic Fatty Liver Disease
por: Cadar, Ramona, et al.
Publicado: (2023)

Reported Barriers to Hepatitis C Treatment among Pregnant and Early-Parenting Mothers Undergoing Substance Use Disorder Treatment in One U.S. State
por: Adekunle, Ayooluwatomiwa Deborah, et al.
Publicado: (2021)

3442 Among Hospitalized Patients, Cannabis use is Associated with Reduced risk of Clostridium Difficile infection
por: Adejumo, Adeyinka Charles, et al.
Publicado: (2019)

Correction: Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications
por: Axley, Page, et al.
Publicado: (2018)

Pathogenesis, Early Diagnosis, and Therapeutic Management of Alcoholic Liver Disease
por: Kong, Ling-Zu, et al.
Publicado: (2019)

Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease
por: Hyun, Ji Ye, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8201lqgm8skqcore19rkg7m879